Abstract 1737
Background
Deletion 17p (del17p) is a rare genomic aberration found in patients with CLL and its incidence is 5-9% in untreated patients and 30- 50% of relapsed and refractory cases. The presence of del 17p correlates with poor response to chemotherapy and unfavourable outcome. There is a paucity of data regarding incidence and outcome of CLL patients with del 17p from India.
Methods
This prospective study included consecutive treatmentnaïve and relapsed/refractory patients who were diagnosed with CLL and registered at the Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, between June 2013 and December 2018. Del 17p was assessed by FISH in peripheral blood samples.
Results
Total 220 patients (150 new and 70 relapse/refractory) recruited in this study, del 17 p was found in 18 (12%) patients in new cases and 18 (25.5%) in relapsed/refractory cases. The median age in 36 cases were 57 years (35-80) with male:female ratio was 6:1. As per clinical Rai stage:5 cases were in stage 0 & I, 10 cases were in stage II, 8 cases were in stage III and 13 cases were in stage IV. ZAP-70 was positive in 58%, CD 38 was positive in 45%, CD49d was positive in 66% and 80% of cases were IGVH unmutated. Out of 18 newly diagnosed cases, 11 patients received treatment [ 4 – Ibrutinib, 4 -Bendamustine + Rituximab (BR), 2- Chlorambucil and Prednisolone (CP),1 -Fludarabine, cyclophosphamide and rituximab (FCR)] while 7 patients were kept under observation. The overall response rate was 63.6% and complete response was 4 (36.36%). Out of 18 Relapse/refractory cases, 15 patients were required treatment (4- Ibrutinib, 4- BR, 5 -RCHOP/RCVP, 2 CP] with an overall response rate of 40% and CR rate of 12%. Eighteen patients died (11-disease progression, 4 infections and 3 -other reasons). Eight patients developed Richter’s transformation and died. The median progression free survival and overall survival was 14 months and 24 months respectively.
Conclusions
This is the first study on CLL with del17 p reported from India. Its incidence is 12 % in upfront cases and 25.5% in relapsed /refractory cases. Chemoimmunotherapy has dismal outcome and Ibrutinib was used in a limited number of patients because of financial constraints.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract